Walden Group Healthcare M&A Blog

  • Abbott Laboratories to Acquire Cephea Valve Technologies

    01/16/2019
    Abbott Laboratories, a $20.4b global developer of diagnostics, medical devices, nutritionals and branded generic pharmaceuticals is buying Cephea Valve Technologies, Inc, a developer of a less-invasive heart valve replacement technology for mitral valve disease. The deal Strengthens Abbott's in structural heart therapies. Cephea's artificial...
    Read More
  • Bristol-Myers Squibb Buying Celgene for $74b

    1/3/2019
    Bristol-Myers Squibb Company, a $20.8b global biopharma company is buying Celgene Corporation, a $13b developer of therapies for cancer and inflammatory diseases. The Deal strengthens Bristol-Myers in oncology, cardiovascular disease, immunology and inflammation. Celgene is known for its blockbuster Thalomid and Revlimid cancer drugs. The...
    Read More
  • GlaxoSmithKline to Acquire Tesaro for $5.1b

    12/3/2018
    GlaxoSmithKline plc (GSK), a large European-based pharmaceutical manufacturer is acquiring TESARO Inc., an oncology-focused biopharmaceutical company. The transaction accelerates GSK's commercial capability in oncology. TESARO's major marketed product is Zejula (niraparib), an oral, once-daily ribose polymerase (PARP) inhibitor approved for use...
    Read More
  • Colfax to Acquire DJO Global for $3.15b

    11/20/2018
    Colfax Corporation, a $3.6b diversified maker of fluid handling and other engineered products is acquiring DJO Global Inc, a leading maker of orthopedic bracing and other non-invasive rehab devcies. The deal diversifies CFX' revenue streams and end-market exposure, reduces cyclicality, weights healthcare and creates a new growth platform for CFX....
    Read More
  • With $1.6B Mazor Robotics Buy, Medtronic Spine is All-in

    10/22/2018
    Medtronic Plc (NYSE:MDT), agreed to buy Mazor Robotics Ltd. (NASDAQ:MZOR), a maker of robotic guidance systems, for $1.64bto strengthen its position in spine surgery. Medtronic’s spine division had been hit off-stride after the problems encountered with Kyphon purchase in 2007. Sales force flux, off-label use of a controversial biologics...
    Read More
  • Page 3 of 1312345...10...Last »